TIL · Instil Bio, Inc.
$6.95
-0.27 (-3.74%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“As discussed above and in Note 10 to the accompanying condensed consolidated financial statements, the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$48.63M
Shares
6.78M
Volume · Oct 5
12.94K
Avg daily vol (3M)
11.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.95
Open$7.22
Day$6.95–7.35
52W close$6.66–21.10
Avg vol 30d14K
Short int162K · 2.4% float · 13.1d
Short vol48%
DataMar 2021–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$30.28M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
-58.9%
Trailing year
Short interest
2.4%
Latest settlement · 13.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−6%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−18%
trailing
YTD return
−37%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-19% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.39% of float · ▲ +3.2% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
26 holders — near 3-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+6%
Y/Y
Free cash flow
$-36.6M
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Mar 31, 2023
Quarterly cash burn
· starting in the second half of 2023 through the end of 2024
up to $10M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-19% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.39% of float · ▲ +3.2% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
26 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $7
Now $7 · 2%
Range high $21
vs 200-day avg -13%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TIL
this stock
Instil Bio, Inc.
|
$48.63M | -36.8% | -100.0% | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TIL | -1.3% | -8.3% | -17.7% | -4.0% | -36.8% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -2.5% | -8.9% | -29.2% | -5.6% | -50.4% |